Oncology · PD-1 InhibitorRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for OPDIVO (Nivolumab) by Bristol Myers Squibb

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Bristol Myers Squibb38 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 12:32:28 AM

Assessment confidence: 90% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for OPDIVO is significant as it may lead to new indications that enhance its competitive positioning in the oncology market. This development necessitates close monitoring of the approval timeline and potential impacts on competitors in the PD-1 inhibitor space. Regulatory context from FDA (FDA AP — OPDIVO (SUPPL)) supports the near-term read. Assessment grounded in 30 ranked evidence items (30 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this supplemental application on OPDIVO's competitive landscape and potential new indications. The strongest clinical anchor is PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov), mechanism alignment (pd-1); sponsor/company relevance (bristol myers squibb). In Oncology · PD-1 Inhibitor, 7 regulatory and 8 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves KEYTRUDA and KEYTRUDA QLEX for Muscle-Invasive Bladder Cancer (Humanexa Signals) — mechanism alignment (pd-1); sponsor/company relevance (merck). Secondary pressure from U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — OPDIVO (SUPPL) (FDA). Entity match (bristol myers squibb).

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, OPDIVO could capture additional market share and revenue from new indications, potentially affecting the sales of competing PD-1 inhibitors.
Upside for Bristol Myers Squibb may improve if PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Bristol Myers Squibb may improve if Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors (ClinicalTrials.gov) delivers favorable follow-through.
Bristol Myers Squibb document relevant to the signal.
Upside for Bristol Myers Squibb may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent announcements regarding approval outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — OPDIVO (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — OPDIVO QVANTIG (SUPPL)
FDAhigh relevance
Entity match (opdivo)
FDA document
View source
FDA AP — OPDUALAG (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Investigational New Drug (IND) Application
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.govhigh relevance
Mechanism alignment (PD-1); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
ClinicalTrials.govhigh relevance
Mechanism alignment (PD-1); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea:
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

FDA Approves KEYTRUDA and KEYTRUDA QLEX for Muscle-Invasive Bladder Cancer
Humanexa Signalshigh relevance
Mechanism alignment (PD-1); Sponsor/company relevance (Merck)
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.
PubMedhigh relevance
Mechanism alignment (PD-1); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
OPDIVO

Commercial impact

medium

If approved, OPDIVO could capture additional market share and revenue from new indications, potentially affecting the sales of competing PD-1 inhibitors.

Regulatory impact

medium

The acceptance of this supplemental application indicates a pathway for potential label expansion, which could influence compliance and regulatory strategies for Bristol Myers Squibb and its competitors.

What to watch

Monitor the FDA's review timeline and any subsequent announcements regarding approval outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.